Zimmer Biomet (NYSE:ZBH) Rating Increased to Hold at Zacks Research

Zimmer Biomet (NYSE:ZBH) was upgraded by research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report issued on Tuesday,Zacks.com reports.

Several other research analysts also recently weighed in on ZBH. Robert W. Baird set a $104.00 target price on shares of Zimmer Biomet in a research report on Thursday, August 6th. JPMorgan Chase & Co. reduced their price target on shares of Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating for the company in a research report on Wednesday, April 29th. Royal Bank Of Canada raised their price objective on shares of Zimmer Biomet from $101.00 to $110.00 and gave the stock an “outperform” rating in a research note on Thursday, August 6th. Canaccord Genuity Group lifted their price objective on shares of Zimmer Biomet from $83.00 to $100.00 and gave the stock a “hold” rating in a research report on Monday, August 10th. Finally, Weiss Ratings raised shares of Zimmer Biomet from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $104.42.

Zimmer Biomet Trading Up 1.2%

Shares of NYSE ZBH opened at $101.41 on Tuesday. The company has a quick ratio of 0.94, a current ratio of 1.69 and a debt-to-equity ratio of 0.50. Zimmer Biomet has a 12 month low of $79.12 and a 12 month high of $107.85. The company has a market cap of $19.34 billion, a price-to-earnings ratio of 24.67, a P/E/G ratio of 2.72 and a beta of 0.45. The business has a fifty day simple moving average of $93.40 and a 200-day simple moving average of $91.31.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share for the quarter, topping analysts’ consensus estimates of $2.01 by $0.06. The firm had revenue of $2.18 billion for the quarter, compared to analysts’ expectations of $2.13 billion. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.Zimmer Biomet’s revenue was up 4.8% on a year-over-year basis. During the same quarter last year, the business posted $2.07 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Sell-side analysts predict that Zimmer Biomet will post 8.54 EPS for the current year.

Insider Activity

In other news, insider Sang Yi sold 5,000 shares of the stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $82.64, for a total value of $413,200.00. Following the completion of the sale, the insider directly owned 27,251 shares of the company’s stock, valued at $2,252,022.64. This represents a 15.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.28% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. DV Equities LLC acquired a new stake in shares of Zimmer Biomet during the 4th quarter valued at $25,000. Tacita Capital Inc purchased a new stake in shares of Zimmer Biomet during the second quarter worth $26,000. Ancora Advisors LLC purchased a new position in Zimmer Biomet in the second quarter valued at about $29,000. Monetary Solutions Ltd acquired a new position in Zimmer Biomet in the 4th quarter worth about $30,000. Finally, Gen Wealth Partners Inc acquired a new position in Zimmer Biomet in the 4th quarter worth about $31,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.